Abstract 258P
Background
Ovarian cancer leaves a detrimental effect on sexual health due to treatment modalities, hormonal imbalance, inability to accept body image after treatment related deformity and other psychological reasons. As the proportion of ovarian cancer survivors is increasing, it is very important to address the issue of sexual health in these patients, an issue which is generally unaddressed. The aim of our study was to asses sexual health in patients treated for ovarian cancer who were disease free at the time of analysis.
Methods
This single institute prospective study was conducted from April 2017 to November 2017. During the routine follow up visit to the hospital, patients who were disease free were recruited in the study. European Organisation of Research and Treatment for Cancer (EORTC) QLQ-OV 28 questionnaire was used to assess the sexual health. The impact of various factors on quality of life (QOL) scores was analysed using one-way analysis of variance (Univariate ANOVA). A p value of < 0.05 was considered as statistically significant.
Results
A total of 84 ovarian cancer patients were recruited. Median age at presentation was 45 years. All patients were clinically and biochemically disease free at the time of analysis. Seventy-two patients were married whereas 12 women were either unmarried or divorced or widows. Out of these 72 women, only 34 (47%) women were found to have had sex in last 3 months. A median score of 33.3 (22.2-66.6) was recorded for sexual function in QLQ-OV 28 questionnaire which was lesser than other domains of functional scale. The sexual score was significantly affected by presence of co-morbidities (p < 0.007), higher number of chemotherapy cycles (p < 0.001), fear of recurrence (p < 0.02), vaginal dryness and pain (p < 0.04).
Conclusions
Sexual health is a fundamental quality of life domain which is often compromised and underestimated in ovarian cancer patients. The present study showed that diagnosis and treatment of ovarian cancer has a negative impact on sexual health. As the proportion of ovarian cancer survivors continuously rising, there is a need to acknowledge and address the impact of treatment on sexual health.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
All authors have declared no conflicts of interest.
Resources from the same session
87P - Negative to positive lymph node ratio-prognostic marker of survival in node positive rectal cancer
Presenter: Pavan Jonnada
Session: Poster display session
Resources:
Abstract
88P - The Sidra LUMC advanced colon cancer NGS cohort
Presenter: Wouter Hendrickx
Session: Poster display session
Resources:
Abstract
89P - A phase II trial of adjuvant chemoradiotherapy for patients with high-risk rectal submucosal invasive cancer after local resection
Presenter: Masaaki Noguchi
Session: Poster display session
Resources:
Abstract
90P - High MICB expression confers prognostic benefit in colorectal cancer
Presenter: Shanchao Yu
Session: Poster display session
Resources:
Abstract
91P - Adjuvant therapy for high-risk stage II or stage III colon adenocarcinoma: A propensity score-matched, nationwide, population-based cohort study
Presenter: Chien-Hsin Chen
Session: Poster display session
Resources:
Abstract
92P - Prospective randomized controlled study comparing primary surgery versus neoadjuvant chemotherapy followed by surgery in gastric carcinoma
Presenter: Vipin Goel
Session: Poster display session
Resources:
Abstract
93P - Biomarker selection of liver metastatic colorectal patients for anti-EGFR monoclonal antibodies: A machine learning analysis
Presenter: Yijiao Chen
Session: Poster display session
Resources:
Abstract
94P - NORTH/HGCSG1003: North Japan multicenter phase II study of oxaliplatin-containing regimen as adjuvant chemotherapy for stage III colon cancer: Final analysis
Presenter: Michio Nakamura
Session: Poster display session
Resources:
Abstract
95P - Anatomical resections improve relapse-free survival in patients with KRAS/NRAS/BRAF- mutated colorectal liver metastases
Presenter: Ye Wei
Session: Poster display session
Resources:
Abstract
96P - Incidence, characteristics and prognosis in colorectal cancer with CNS metastases
Presenter: Nicola Taylor
Session: Poster display session
Resources:
Abstract